Palantir Technologies Inc., a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics , the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.
Recommended AI News : Nigeria Largest Telco, MTN, Launches RCS Business Messaging with Google And Dotgo
Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with other data sources, including data from the published literature and databases, to identify new compounds and therapeutic approaches.
Dewpoint will also use Foundry as the primary platform for its centralized knowledge repository, helping it contextualize its experimental results and prioritize the most viable outcomes. This multi-year agreement marks one of Palantir’s most comprehensive partnerships with a biotechnology company.
Palantir Foundry is designed to integrate disparate and siloed information sources to lead to data-driven analysis and decision making. It allows users to track lineage across systems, making it particularly suited for work in life sciences and the biotechnology sector, where data sources come from several unique and separate systems.
At Dewpoint, Foundry will be able to work seamlessly with the existing systems in its laboratories to provide researchers with a comprehensive foundation for exploration and analysis.
Recommended AI News: Fortinet Continues To Expand Secure SD-WAN Globally With New Service Provider Partnerships
“We think Dewpoint is changing the way the world approaches drug design by exploring new frontiers of disease biology, requiring a game changing solution that goes beyond just cloud and infrastructure to drive their R&D and scale with their vision as they grow,” said Lalarukh Haris Shaikh, Palantir’s Head of Biotech. “We are proud to partner with Dewpoint and share their passion of working on one of the most exciting translational medicine approaches of our time.”
Foundry will help researchers make decisions around compound and target viability and streamline experiments and automate analysis by creating a digital twin of the research environment. One concrete example of Foundry’s use at Dewpoint Therapeutics is the expansion of the data foundation to include advanced genetic analysis for disease association and correlation with condensate content, empowering future discoveries.
“Key to our approach has been creating a seamless connection between our wet-lab and dry-lab capabilities, with machine learning and AI at the center. Foundry has provided us with a solid foundation for us to fully connect and operationalize our entire lab to enterprise and enable the discovery and development of new drugs,” said Dewpoint CEO Ameet Nathwani.
Biggest Ads of 2021: Can You Guess The 2021’S Most Emotionally Engaging Holiday Ads In The APAC Region?
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.